Expand all sections

Leuco-methylthioninium

LMTX

Extended indication Alzheimer’s disease, mild-to-moderate.
Therapeutic value No judgement
Registration phase Clinical trials

Product

Active substance Leuco-methylthioninium
Domain Neurological disorders
Main indication Dementia
Extended indication Alzheimer’s disease, mild-to-moderate.
Proprietary name LMTX
Manufacturer TauRx
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Particularity New medicine
Expected Registration 2019
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Therapeutic value No judgement
Additional remarks Zou mogelijk een nieuwe 1e lijns behandeling kunnen worden.

Expected patient volume per year

Patient volume

< 21,000

Market share is generally not included unless otherwise stated.
References http://www.levenmetalzheimer.nl/content/alzheimer/feiten-cijfers.asp, https://www.sfk.nl/publicaties/PW/2016/inzet-medicijnen-bij-dementie-loopt-terug
Additional remarks In Nederland zijn 270.000 mensen dement. Hiervan hebben 160.000 tot 190.000 mensen de ziekte van Alzheimer (max 70%). In totaal waren er in totaal 30.000 geneesmiddelengebruikers, die medicijnen kregen tegen dementie (SFK), uitgaande van 70% zal het maximaal gaan om 21000 patiënten. Afhankelijk van de therapeutische waarde kan dit aandeel patiënten oplopen.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.